Company
Leadership
The scientific and commercial direction of CTD is guided by decades of hands-on experience in cyclodextrin chemistry, pharmaceutical formulation, and global supply chain management.
Dr. Jeffrey Tate
Chief Scientific Officer & Chief Executive Officer
Dr. Jeff Tate serves as the Chief Scientific Officer and Chief Executive Officer of CTD, a division of CTD Holdings, Inc. With over 25 years of experience in cyclodextrin chemistry and pharmaceutical formulation, Dr. Tate has been instrumental in expanding the commercial applications of both native and modified cyclodextrins.
Under his leadership, CTD has grown from a specialized reagent supplier to the world's largest catalog of cyclodextrin derivatives. His focus on a “Science-First” supply chain has ensured that every Trappsol® and Aquaplex® product meets the rigorous analytical standards required for advanced pharmaceutical research and development.
Dr. Tate is a frequent contributor to scientific literature on the applications of sulfobutyl ether cyclodextrins in parenteral formulations and continues to lead CTD's internal R&D initiatives for orphan disease therapies.
Work with our team
For scientific partnerships, custom synthesis, or bulk inquiries.